Risdiplam Patent Expiration

1. Evrysdi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9586955 GENENTECH INC Compounds for treating spinal muscular atrophy
Feb, 2033

(8 years from now)

US9969754 GENENTECH INC Compounds for treating spinal muscular atrophy
May, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11827646 GENENTECH INC Compounds for treating spinal muscular atrophy
Jan, 2036

(11 years from now)

US11938136 GENENTECH INC Compositions for treating spinal muscular atrophy
Nov, 2036

(12 years from now)

US11534444 GENENTECH INC Treatment of SMA
Oct, 2038

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) May 27, 2025
New Chemical Entity Exclusivity(NCE) Aug 07, 2025
M(M-270) Oct 03, 2026
Orphan Drug Exclusivity(ODE-334) Aug 07, 2027
Orphan Drug Exclusivity(ODE-400) May 27, 2029

NCE-1 date: 07 August, 2024

Market Authorisation Date: 07 August, 2020

Treatment: Treatment of spinal muscular atrophy

Dosage: FOR SOLUTION

More Information on Dosage

EVRYSDI family patents

Family Patents